|Articles|December 8, 2003

Datascope Announces Safeguard Hemostasis Device

MONTVALE, N.J. -- Datascope Corp. announces the worldwide launch of Safeguard, an innovative, inflatable pressure-dressing designed to maintain hemostasis after manual compression for arterial catheterization procedures. Safeguard will compete in an estimated $54 million worldwide market for devices that assist manual compression. The company believes that most of this market opportunity is currently in the U.S. Manual compression is still used to control bleeding in a majority of an estimated 4.8 million catheterization procedures in the U.S. market.

Safeguard is a single-use adhesive dressing with an inflatable see-through plastic bulb. The user places Safeguard over the patient's puncture wound site and inflates the bulb with air from a syringe. The inflated bulb is inelastic and provides consistent pressure over the wound site to maintain hemostasis. The see-through bulb allows easy monitoring of the wound site.

After completing an evaluation of Safeguard at the Lenox Hill Hospital of New York, Dr. Jeffrey Moses, chief of interventional cardiology, said, "Safeguard is easy to use, effective and reliable." The device proved effective at maintaining hemostasis following femorally accessed coronary catheterization procedures, adhering to wound sites reliably for hours, and producing no complications.

"Because Safeguard is so effective and easy to use, we expect to see many applications besides cath procedures where hemostasis needs to be maintained. Safeguard is off to a good start in the market," said Tim Shannon, vice president of aales for Datascope's Interventional Products Division that manufactures and markets Safeguard.

Datascope Corp. is a diversified medical device company that manufactures and markets proprietary products for clinical healthcare markets in interventional cardiology and radiology, cardiovascular and vascular surgery, anesthesiology, emergency medicine and critical care.

Source: Datascope Corp.


Related to this article

Water  (Adobe Stock 456102510 by stockphoto-graf)
Understanding current water quality is a starting point for ST108 implementation. John Kimsey, vice president of processing optimization and customer success for STERIS, spoke about his HSPA presentation on assessing readiness, distinguishing system qualification from routine testing, and understanding where water samples should be collected.
Image of Pathogens flying   (Adobe Stock weerasak)
Behind every landmark in infection prevention, from antimicrobial stewardship guidelines to the COVID-19 town halls that reached flight attendants and teachers, is a generation of physician-scientists who led SHEA through crises, organizational change, and scientific breakthroughs. Infection Control Today traces 30 years of SHEA presidents and the lasting mark they left on the field.
AORN26 New Orleans 2026  (Adobe Stock)
Missing instruments and processing delays can strain OR–SPD relationships. At AORN 2026, John Kimsey, vice president of processing optimization and customer success for STERIS, discusses understanding root causes, exploring off-site reprocessing for ambulatory surgical centers, and using hands-on simulation to help surgical teams see sterile processing from a different perspective.